Introduction
============

After cardiovascular disease, respiratory diseases rank second in terms of mortality, incidence, prevalence, and costs. The European prevalence of chronic obstructive pulmonary disease (COPD) ranges from \<2% in France and the UK, to 9% in Spain ([@b65-copd-2-191]), and \>10% in Germany and Italy ([@b27-copd-2-191]). Moreover, a European-wide increase in the prevalence and mortality of COPD and other smoking-related diseases, particularly in women, is projected for the coming decades ([@b56-copd-2-191]). Chronic bronchitis (CB), a component of COPD, usually associated with frequent exacerbations, is even more prevalent; as an example, 4.1% of the French population aged 25+ years develop this disease ([@b21-copd-2-191]). Nonetheless, the prevalence of CB differs between countries. In a recent study of young European adults, the prevalence of CB in subjects aged 20--44 years ranged from 0.7% in the UK to 9.7% in Spain ([@b14-copd-2-191]), with the prevalence being directly associated with smoking prevalence ([@b6-copd-2-191]).

Due to the high prevalence and chronic course of these conditions, COPD and CB represent a great burden to society. The mean annual direct medical costs of a COPD patient are an estimated €1800, with 42% of the costs being due to hospitalisations, most because of exacerbations ([@b45-copd-2-191]). Each exacerbation treated in the community has a mean cost of €175, but costs are higher for complicated exacerbations requiring hospital admission ([@b44-copd-2-191]).

In addition, COPD and CB are debilitating conditions affecting fundamental aspects of everyday life including normal physical exertion, work, and social and family activities ([@b51-copd-2-191]). Chronic lung disease thus has substantial effects on health-related quality of life (HRQoL), with increasing CB severity and factors such as frequency and nature of exacerbations being associated with increasing symptoms and deteriorating HRQoL ([@b62-copd-2-191]; [@b47-copd-2-191]). HRQoL has been found to be significantly adversely affected during exacerbations with increased anxiety about breathlessness and the coughing up of phlegm in public ([@b52-copd-2-191]).

Bacterial are isolated in 50%--75% of exacerbations ([@b32-copd-2-191]; [@b54-copd-2-191]). Because of the difficulties in establishing a bacteriological diagnosis of respiratory tract infections (RTIs) in ambulatory clinical practice, it is common practice to commence antibiotic treatment empirically. In an analysis of initial antibiotic treatment in Europe for all infections, including RTIs, 85% of these therapies were started empirically ([@b19-copd-2-191]). In view of the limits of the spectrum of activity of some antibiotics, as well as the increasing prevalence of bacterial resistance to older generation agents, multiple antibiotics are administered in some cases of RTIs or when resistant or polymicrobial infection is suspected ([@b64-copd-2-191]). There is a continued need to find antibiotics that can be used in empiric treatment regimens so that the patient responds rapidly and the risk of development of resistance is limited.

Moxifloxacin hydrochloride (Avelox^®^, Bayer AG) is a fluoroquinolone that has been shown to be effective against *Moraxella catarrhalis*, *Haemophilus influenza*, and multi-drug resistant pneumococcal strains ([@b5-copd-2-191]; [@b58-copd-2-191]; [@b34-copd-2-191]). Moxifloxacin is strongly targeted to alveolar tissue ([@b66-copd-2-191]; [@b31-copd-2-191]), and has shown rapid initial killing and eradication rates for pneumococcal bacteria ([@b25-copd-2-191]).

This paper will focus on recent advances in the study of antimicrobial treatment of exacerbations of CB and COPD with moxifloxacin. In this respect, new trials have documented improved outcomes related to time to resolution of symptoms and extended time to the next exacerbation. These new outcomes derive from the better understanding of the natural history of CB and COPD and their exacerbations.

Pharmacology
============

Mechanism of action
-------------------

Moxifloxacin is a forth generation fluoroquinolone with bactericidal activity as a result of its interference with topoisomerase II (DNA gyrase) and IV ([@b60-copd-2-191]). Topoisomerases are essential enzymes which play a crucial part in the replication, transcription, and repair of bacterial DNA. Topoisomerase IV is also known to influence bacterial chromosome division. Kinetic investigations have demonstrated that moxifloxacin exhibits a concentration-dependent killing rate; minimum bactericidal concentrations (MBC) were found to be within the range of the minimum inhibitory concentrations (MIC) ([@b68-copd-2-191]; [@b22-copd-2-191]).

Antimicrobial activity
----------------------

Moxifloxacin demonstrates excellent in vitro activity (as assessed by MIC~90~ concentrations of 0.06 to 0.25 mg/L) against all the predominant respiratory pathogens including Gram-positive (*Streptococcus pneumoniae*), Gram-negative (*H. influenzae*, *M. catarrhalis*), anaerobic (peptostreptococci or *Prevotella* spp.), and atypical strains (*C. pneumoniae*, *M. pneumoniae*). Against both beta-lactamase positive and negative *M. catarrhalis* and *H. influenzae*, MIC~90~ values to moxifloxacin were ≤0.06 μg/mL. Similarly, moxifloxacin MIC~90~ values ranged from 0.06 to 0.25 μg/mL against clinical isolates of *S. pneumoniae* regardless of penicillin susceptibility ([@b77-copd-2-191]; [@b5-copd-2-191]) (Table [1](#t1-copd-2-191){ref-type="table"}).

Pharmacokinetics
----------------

Following oral administration moxifloxacin is rapidly and almost completely absorbed, with an absolute bioavailability of approximately 91% ([@b69-copd-2-191]). Its penetration into pulmonary tissues is excellent and concentrates in alveolar macrophages (Table [2](#t2-copd-2-191){ref-type="table"}). Following a 400 mg oral dose, peak concentrations of 3.1 mg/L are reached within 0.5--4 hours post administration. Peak and trough plasma concentrations at steady-state (400 mg once daily) are 3.2 and 0.6 mg/L, respectively. Moxifloxacin is rapidly distributed to extra-vascular spaces; and an area under the concentration-time curve (AUC) of 35 mg·h L^−1^ is observed after a dose of 400 mg. Moxifloxacin is mainly bound to serum albumin. In vitro and ex vivo experiments have shown a protein binding of approximately 40%--42%, independently of the concentration of the drug ([@b66-copd-2-191]; [@b71-copd-2-191]).

Moxifloxacin is eliminated from plasma with a mean terminal half-life of approximately 12 hours ([@b68-copd-2-191]). After a 400 mg dose, recovery of parent compound and metabolites of moxifloxacin from urine and feces totals approximately 96% (Table [3](#t3-copd-2-191){ref-type="table"}).

The pharmacokinetic and pharmacodynamic parameters for antibacterial agents can be integrated into the ratio of the AUC to MIC~90~, or area under the inhibition curve (AUIC), ie, the AUC/MIC normalized for 24 hours ([@b61-copd-2-191]).

Agents with a low C~max~, short t~1/2~ and low in vitro activity against a specific pathogen (viz: higher MIC~90~ values) have a lower AUIC than those with high C~max~, prolonged t~1/2~ and high in vitro activity. Quinolones with AUIC values above 85--125 and C~max~ to MIC ratios of 8--10 have been associated with better clinical and bacteriological cure rates compared with agents with lower AUIC values ([@b17-copd-2-191]). High AUIC values indicate rapid eradication of pathogens and a reduced likelihood of resistance development, as pathogens are killed before they have time to mutate ([@b61-copd-2-191]).

Compared with other fluoroquinolones, moxifloxacin has the highest AUIC ratio against *S. pneumoniae* (192--400 35 mg·h L^−1^) ([@b76-copd-2-191]) (Table [3](#t3-copd-2-191){ref-type="table"}). Despite achieving good tissue penetration, levofloxacin is only moderately active against *S. pneumoniae*, whereas gatifloxacin is more bactericidal but only achieves modest tissue levels. Levofloxacin does not have the chemical structure of moxifloxacin to fight resistance, eg, a methoxy moiety at position C-8 -- a substitution that has been shown to select for mutants much less frequently than a hydrogen moiety ([@b76-copd-2-191]). In addition, moxifloxacin has a 7-azabicyclo side chain that makes it more difficult to efflux the antibiotic out of the bacterial cell ([@b76-copd-2-191]).

The approved dose and regimen of oral moxifloxacin for the indication of exacerbations of CB is: 400 mg orally once daily for 5--7 days.

Efficacy of moxifloxacin in exacerbations of chronic bronchitis and COPD
========================================================================

Registration clinical trials
----------------------------

The clinical program for moxifloxacin included four studies comparing the efficacy and safety of moxifloxacin (400 mg once daily, 5 days) with either clarithromycin (500 mg twice daily, 7--10 days) or cefuroxime-axetil (500 mg twice daily, 10 days) in 2381 patients with exacerbations of CB ([@b34-copd-2-191]).

The clinical and bacteriological success rates 7--14 days post-treatment were comparable between the three treatment groups. However, there was a trend towards improved bacteriological success after 5 days of moxifloxacin therapy compared with 7--10 days of clarithromycin treatment. The three treatment regimens were also similar with respect to eradication of *S. pneumoniae* and *M. catarrhalis*. In contrast, moxifloxacin showed improved eradication rates against *H. influenzae* (129/132, 97%) as compared with clarithromycin (62/86, 72%) ([@b53-copd-2-191]). Taken together, the studies of the clinical program demonstrated that treatment with moxifloxacin 400 mg once daily for 5 days achieves a clinical response rate of 89% and a bacteriological response rate of 87% ([@b34-copd-2-191]).

Clinical studies of antimicrobials in exacerbations of CB such as those performed in the original clinical program have been limited by factors such as inadequate information on patient condition prior to the exacerbation and lack of long-term follow-up, as well as a lack of prospective control for steroid use, which can positively affect the outcome of the episode ([@b47-copd-2-191]), and for prognostic factors that can have a negative impact ([@b15-copd-2-191]; [@b43-copd-2-191]) (Table [4](#t4-copd-2-191){ref-type="table"}). After the registration trials, new studies have been designed to evaluate the clinical efficacy of moxifloxacin in different patient populations with exacerbations of chronic bronchial disease. In parallel, new outcomes have been analyzed in this new generation of clinical trials.

Clinical efficacy of moxifloxacin: short-term outcomes
------------------------------------------------------

The MOSAIC study ([@b74-copd-2-191], [@b75-copd-2-191]) was a multicenter, multinational, randomized study of two parallel treatment arms including outpatients aged \>45 years with stable CB, history of smoking of ≥20 packs/year, ≥2 documented exacerbations in the previous year, and FEV~1~\<85% of predicted value. Patients with a severe exacerbation of CB within 12 months of enrolment were randomized to receive either oral moxifloxacin 400 mg once daily for 5 days or one of the comparators: amoxicillin 500 mg tid for 7 days, clarithromycin 500 mg bid for 7 days or cefuroxime-axetil 250 mg bid for 7 days. Patients were assessed at screening, end of treatment and 7--10 days after treatment, and were contacted by phone monthly until a new exacerbation occurred or up to a maximum of 9 months. Clinical cure was defined as a return to pre-exacerbation status, and clinical success as cure and improvement combined, overall and by strata of steroid use and prognostic factors. Other efficacy measures were needed for further antimicrobials, time to next exacerbation, and bacteriological treatment success. Of 1935 enrolled patients, 733 (37.9%) had severe (Anthonisen type I) exacerbation within 12 months of screening and were randomized; 730 receiving either moxifloxacin (n = 354) or comparator (n = 376). Clinical success was seen in 83.0%--87.6% of patients across treatment arms and populations, with statistical equivalence in all populations except a significant difference in favor of moxifloxacin patients not receiving steroids. However, clinical cure rates were significantly higher with moxifloxacin (70.9%) compared with the comparators (62.8%) (95% confidence interval (CI) of the difference = 0.3%--15.6%); the clinical cure rate was also significantly greater in the moxifloxacin arm when analyzed by prognostic factors of age, airway obstruction, number of exacerbations of CB in the previous year, duration of CB and cardiopulmonary comorbidity ([@b74-copd-2-191]).

Bacterial eradication with moxifloxacin in bacteriologically evaluable patients was significantly higher with moxifloxacin compared with the control antibiotics (91.5% vs 81%; 95% CI = 0.4%--22%) ([@b74-copd-2-191]). Bacterial eradication with moxifloxacin has been demonstrated to be superior compared with macrolides. In a pooled analysis of moxifloxacin phase III trials compared with macrolide agents in eradication of *H. influenzae*, the results showed superiority of moxifloxacin against both azithromycin and clarithromycin. Eradication of *H. influenzae* with moxifloxacin was 93% (133/143) compared with 73.2% (109/149) with macrolides, p = 0.001. Considering both macrolides separately, eradication rates were 96.8% with moxifloxacin vs 84.6% with azithromycin (p = 0.019) and 90.1% with moxifloxacin vs 64.3% with clarithromycin (p = 0.001) ([@b53-copd-2-191]) (Figure [1](#f1-copd-2-191){ref-type="fig"}).

The results of the MOSAIC trial also showed that up to 14.8% of patients treated with a comparator antibiotic required a second prescription of antibiotics to control symptoms of exacerbation, compared with only 8.8% of patients randomized to receive moxifloxacin (p = 0.03) ([@b74-copd-2-191]).

Although initially designed to demonstrate non-inferiority of moxifloxacin over standard therapy, the MOSAIC study was the first clinical trial to demonstrate the superiority of an antibitic, moxifloxacin, over the comparators in clinical cure and bacteriological eradication rates.

A recent publication has provided a systematic analysis and meta-analysis of published clinical trials with moxifloxacin in the treatment of exacerbations of CB up to June 2005 ([@b42-copd-2-191]) with the objective to determine the superiority of moxifloxacin over standard therapy in this indication. A total of 45 studies were identified, but only 9 fulfilled the inclusion criteria in the meta-analysis. Of them, 5 were randomized and double-blind and 4 were randomized and open labeled.

All studies concluded that the efficacy of treatment with moxifloxacin was at least as good as treatment with the comparator. One of the studies concluded that eradication and cure rates were superior with moxifloxacin versus comparators, as highlighted above ([@b74-copd-2-191]).

The global analysis included 3905 randomized patients and showed an aggregated superior clinical success rate of moxifloxacin of 1.5% (95% CI = −0.4%--3.4%) which did not reach statistical significance, but showed a trend towards a better clinical outcome with moxifloxacin (Figure [2](#f2-copd-2-191){ref-type="fig"}). It is of note that these results were obtained from a combined analysis of studies individually designed to show equivalence between both treatment arms and without enough statistical power to demonstrate superiority.

Long-term outcomes: prevention of exacerbations with moxifloxacin
-----------------------------------------------------------------

The most important unmet need in the treatment of exacerbations of COPD is the prevention of recurrence ([@b35-copd-2-191]). One of the characteristics of the MOSAIC trial was the follow-up period of up to 9 months after recovery from the exacerbation. The hypothesis was that a better eradication rate with moxifloxacin would translate into a prolonged time to the next exacerbation. In 405 patients with new exacerbations during the follow-up period, the mean time to event was 10 days longer with moxifloxacin treatment (127.6 ± 68.1 days) than comparators (116.7 ± 68.8), with more patients receiving the comparator having new exacerbations within 60 days of treatment (51/208, 24.5%) than moxifloxacin (31/197, 15.7%). The log rank test showed a significant difference in favor of moxifloxacin for up to 5 months of follow-up (p = 0.03) ([@b74-copd-2-191]).

In a secondary analysis, the authors attempted to identify the variables independently and significantly associated with a prolonged time to the next exacerbation. Treatment with moxifloxacin was associated with a prolonged time to recurrence (hazard ratio for recurrence with moxifloxacin versus comparators 0.82; 95% CI = 0.68--0.98) ([@b75-copd-2-191]).

This effect of moxifloxacin on time to relapse has not been observed with other fluoroquinolones. In a recent study, levofloxacin was compared with clarithromycin in a group of 434 patients with exacerbations of CB. After a 1-year follow-up, no differences in time free from exacerbation were observed between patients treated with levofloxacin (mean of 100.5 days) or clarithromycin (95 days), p = 0.32 ([@b28-copd-2-191]). These results may be the consequence of a lower antibacterial activity of levofloxacin compared to moxifloxacin or more likely to the inclusion of a milder patient population in the latter study, making clinical differences against macrolides less likely ([@b48-copd-2-191]).

The rationale for the prevention of exacerbations with moxifloxacin derives from a combination of at least three different factors: a) an immunomodulatory effect of the drug ([@b11-copd-2-191]); b) the rapid and more complete eradication prevents epithelial damage and restores the local defence mechanisms of the bronchial mucosa ([@b13-copd-2-191]); c) as a consequence of the better eradication, fewer viable pathogens remain in the bronchial tissue after antimicrobial treatment, requiring longer for the bacterial population to increase sufficiently to induce a new exacerbation ([@b9-copd-2-191]). This last hypothesis is also known as the "fall and rise" hypothesis of bacterial exacerbation of CB ([@b33-copd-2-191]). In clinical trials with antibiotics, a prolonged time to the next exacerbation has been observed in patients who eradicate the bronchial pathogen after an exacerbation compared with those who cured the exacerbation but without effective eradication ([@b8-copd-2-191]). According to the "fall and rise" hypothesis, patients who effectively eradicate bacteria would need a longer time to achieve the threshold of bacterial counts compared with patients who cured the exacerbation but in whom bacteria still persisted after antibiotic treatment ([@b33-copd-2-191]). This hypothesis would also explain why patients with acute exacerbations may be clinically cured even without eradication of the bacterial pathogen ([@b73-copd-2-191]). This is not proof that this particular bacterium is not the cause of the exacerbation, but does demonstrate that the antibiotic only needs to reduce bacterial counts to below the threshold to eliminate symptoms. Nevertheless, if eradication also occurs, the time for a number of bacteria above the threshold to be reached will be longer (Figure [3](#f3-copd-2-191){ref-type="fig"}).

The quantitative or "fall and rise" hypothesis may explain the basic mechanism of bacterial exacerbations in patients with chronic bronchial colonisation and frequent exacerbations. In this group of patients, the change in the serotype of the colonising bacteria may act as a trigger that initiates profileration of microorganisms in some cases. The "fall and rise" can also explain relapses when bacteria have not been eradicated after antibiotic treatment of the exacerbation. In contrast, the change of serotype of infective bacteria may be crucial in patients who do not suffer frequent exacerbations, ie, less than two in a year. It is difficult to explain the appearance of an exacerbation more than four months after a preceding episode based only on bacterial growth in the airways without any precipitating factor, such as change in serotype ([@b63-copd-2-191]). New evidence is required on the complex relationship between microorganisms and the host, particularly considering that important therapeutic implications may be derived from these findings. In fact, if the new exacerbation is caused by the regrowth of the same bacteria that remained unkilled, the logical approach to treatment would be to use a different antibiotic and rotation of antibiotics should be recommended to prevent bacteriological failure and the development of resistance. In contrast, if new exacerbations are caused by the acquisition of new strains, the same antibiotic can be used in repeated exacerbations without concern about increased exposure to the same antibiotic.

Speed of recovery after antibiotic treatment of an exacerbation
---------------------------------------------------------------

Fast recovery of the symptoms of an exacerbation is highly demanded by patients ([@b35-copd-2-191]). Antibiotics that exhibit faster bacterial killing in vitro should provide faster relief of symptoms in patients with exacerbations of CB and COPD.

Observational studies and cross-sectional analyses in patients with CB and COPD have suggested that patients recover from symptoms of exacerbations more rapìdly with moxifloxacin than with other commonly used treatments ([@b23-copd-2-191]; [@b49-copd-2-191], [@b39-copd-2-191]).

One large, multicenter comparative study using a 2-year protocol (IMPAC study) showed a significant reduction in the time to recovery from exacerbations of moderate to severe COPD ([@b49-copd-2-191]). In 441 patients with COPD, all with a FEV~1~ \<50% predicted (mean FEV~1~ = 36% predicted), the investigators treated 614 exacerbations with moxifloxacin (exacerbations = 111) and 503 with either amoxicillin/clavulanate, cefuroxime, or clarithromycin. Moxifloxacin was available in the second study year only. In year 2, exacerbations treated with moxifloxacin resulted in complete recovery from symptoms in a mean of 4.6 days, compared with 5.8 days for the other treatments administered (p = 0.02). In the longitudinal analysis of 27 patients treated with moxifloxacin who had received other treatments in year 1, the mean time to recovery from exacerbations was significantly reduced from a mean of 6.8--3.7 days (p = 0.02). These results were confirmed in another study, the EFEMAP study (Estudio FarmacoEconómico de Moxifloxacino en las Agudizaciones de la EPOC), with mild to moderate COPD patients in primary care centers ([@b39-copd-2-191]). A total of 1456 patients with COPD (mean FEV~1~ = 52% predicted) received either moxifloxacin (n = 575), amoxicillin/clavulate (n = 460), or clarithromycin (n = 421). Clinical success was observed in 97.2%, 93.1%, and 94.4% of the cases, respectively, without significant differences among the groups. However, symptoms of purulence and the volume of expectoration resolved a mean of one day earlier with moxifloxacin compared with the other groups ([@b39-copd-2-191]). In a secondary analysis of the EFEMAP study, the factors associated significantly and independently with a slow recovery (more than 5 days) were the use of long-term oxygen therapy (odds ratio (OR) = 1.97; 95% CI = 1.35--2.85); the increased use of rescue medication with short-acting beta-2 agonists (OR = 1.51; 95% CI = 1.17--1.92); and the use of amoxicillin/clavulanate or clarithromycin compared with moxifloxacin (OR = 2.94; 95% CI = 2.22--3.84 and OR = 2.43; 95% CI = 1.17--3.22, respectively) ([@b40-copd-2-191]). Although all studies consistently indicate a faster resolution of symptoms of exacerbations with moxifloxacin compared to other frequently used antibiotics, these results must be interpreted with caution because they derive from observational studies and, as such, are subjected to possible sources of biases.

A economic analysis derived from the results of the EFEMAP study has shown that exacerbations treated with moxifloxacin generated a direct medical cost similar to those treated with amoxicillin/clavulanate (€111.46; 95% CI =€73.4--149.5 compared with €109.45; 95% CI = €68.2--150.7, respectively); and lower, although not significantly, than those treated with clarithromycin (€138.95; 95% CI = €89.4--188.5). These differences were mainly due to the higher costs associated with relapse in the group treated with clarithromycin ([@b26-copd-2-191]) (Figure [4](#f4-copd-2-191){ref-type="fig"}).

Clinical efficacy of moxifloxacin in patients belonging to risk groups
----------------------------------------------------------------------

Failure rates after ambulatory treatment derive from clinical trials on antibiotics in CB and range from 7% to 12%. Nevertheless, these results cannot be extrapolated to everyday practice, since patients included in clinical trials consist of CB patients and include subjects with ages ranging from 18 to 90 years, a significant proportion of never smokers, and individuals without ventilatory impairment (not COPD) ([@b48-copd-2-191]). However, more recently, some studies have addressed treatment failure in observational "real-life" studies and showed a failure rate ranging from 12% to 26% ([@b15-copd-2-191]; [@b1-copd-2-191]; [@b31-copd-2-191]; [@b43-copd-2-191]; [@b30-copd-2-191]). Identification of risk factors for failure may permit the implementation of more aggressive broad spectrum treatment and closer follow-up. In a further step, risk factors associated with relapse should be incorporated into management guidelines to aid in identifying at-risk patients. Among the risk factors, severity of the underlying pulmonary disease is probably the most important. A summary of the main risk factors for relapse is presented in Table [4](#t4-copd-2-191){ref-type="table"}.

Some of the studies included in the meta-analysis of clinical trials evaluated the efficacy of moxifloxacin in patients belonging to different risk groups. In a study comparing moxifloxacin and amoxicillin-clavulanate ([@b59-copd-2-191]), individuals older than 60 years showed a significantly better success rate with moxifloxacin (p = 0.048) and a tendency towards a better outcome with moxifloxacin in patients with cardiopulmonary comorbidity (p = 0.054). The MOSAIC study has also demonstrated the superiority of moxifloxacin over the comparators in elderly patients and those with a higher number of previous exacerbations ([@b75-copd-2-191]). Table [5](#t5-copd-2-191){ref-type="table"} presents the results of moxifloxacin and comparators in patients belonging to different risk groups.

The main studies of moxifloxacin for the treatment of exacerbations of CB and COPD are summarized in Table [6](#t6-copd-2-191){ref-type="table"}.

Safety
======

Adverse events
--------------

Moxifloxacin has shown a highly favorable safety and tolerability profile in clinical trials as well as in the clinical setting. In a meta-analysis of data from clinical trials and post-marketing surveillance comprising over 25 million patient treatments, the most frequent adverse events reported in clinical trials were nausea (7.1%), diarrhea (5.2%), and dizziness (2.6%) following the administration of a dosage of 400 mg, once daily ([@b3-copd-2-191]). In all cases the frequency of side-effects was not statistically different to that of the comparators. There was no evidence that moxifloxacin caused disturbances in glucose metabolism in patients with or without diabetes mellitus, and there was no evidence of an increased risk of adverse cardiovascular events ([@b3-copd-2-191]).

Conclusions
===========

The prevalence of chronic bronchial diseases caused by tobacco smoking, namely CB and COPD is great in developed and developing countries. Exacerbations constitute the mean cause for medical consultation of patients with these diseases and bacterial infection is involved in more than half of the cases. Most of the microorganisms involved in pathogenesis of exacerbations of CB and COPD have developed diverse degrees of resistance to the traditional antibiotics used as first-line treatment. Development of resistance is caused by the increased volume of prescription, the inadequate indication of the antibiotic and/or inadequate administration or treatment compliance by the patient. Patients with acute (viral) bronchitis and those with exacerbations without changes in the volume or characteristics of sputum should not be treated with antibiotics. When bacterial infection is suspected, there is a growing tendency to treat exacerbations more aggressively with shorter courses of antimicrobials to help reduce antibiotic resistance ([@b55-copd-2-191]). This is possible with the new generation fluoroquinolones such as moxifloxacin. Moxifloxacin is a fourth generation fluoroquinolone that has an excellent in vitro activity against the most common respiratory pathogens and its rapid bactericidal action allows short-course 5-day therapy for exacerbations of CB and COPD. In addition, its long half-life allows administration in single daily doses. The once-daily, short-course administration guarantees better patient compliance and makes the development of resistance less likely.

Moxifloxacin is 4- to 10-fold more active than levofloxacin against *S. pneumoniae*. A greater intrinsic activity is linked with faster eradication and reduced susceptibility of the development of resistance. In fact, some reports have described the development of resistance of *S. pneumoniae* during treatment with levofloxacin ([@b10-copd-2-191]), but no reports have shown the same phenomenon in patients treated with more active fluoroquinolones such as moxifloxacin or gatifloxacin. Therefore, these findings support the concept of "use the best first". The most potent agent of the class should be used as first line therapy to avoid the development of resistance to the entire class of antimicrobials, particularly in moderate to severe cases or those with risk factors for relapse or poor compliance.

Moxifloxacin has demonstrated better eradication in exacerbations of CB and COPD compared to standard therapy, in particular compared to macrolides. The complete eradication of bacteria present in the airways is important for the prevention of resistance development ([@b70-copd-2-191]) and for clinical outcome. The persistence of bacteria after antibiotic treatment of an exacerbation has been associated with increased inflammation, poorer evolution of the baseline disease and early recurrence of exacerbation. Fast and complete eradication of bacteria may induce a "virtuous circle" preserving and/or restoring the integrity of the bronchial mucosa and making it more resistant to further bacterial colonization and the development of exacerbations. In addition, the reduction in the frequency of exacerbations will contribute to preserve pulmonary function and health status ([@b13-copd-2-191]) (Figure [5](#f5-copd-2-191){ref-type="fig"}). In the MOSAIC trial, patients treated with moxifloxacin showed a significantly better eradication, together with an extended time to the next exacerbation compared with the standard treatments.

The results obtained in registration trials of patients with exacerbations of CB and COPD, together with the new trials performed after launching moxifloxacin have had an impact on the development of guidelines of antibacterial treatment of exacerbations. The Canadian guidelines indicate fluoroquinolones as the first-line treatment for patients with exacerbated CB with risk factors (FEV~1~ \<50% predicted, more than 4 exacerbations/year, cardiac disease, use of home oxygen, chronic steroid use or antibiotic use in the past 3 months) and second-line therapy in uncomplicated CB ([@b4-copd-2-191]). The Latin American guidelines recommend moxifloxacin as first-line therapy in exacerbated COPD patients with FEV~1~ between 35% to 50%, those with an FEV~1~ \<35% without risk factors for *Pseudomonas* infection and those with FEV~1~ \>50% with risk factors ([@b2-copd-2-191]). Recent guidelines published in Spain by the Spanish Society of Pneumologists and Thoracic Surgeons and the Spanish Society of Geriatrics recommend moxifloxacin as first-line therapy in patients with suspected bacterial exacerbation of COPD with an FEV~1~ \<50% predicted and without risk factors for *Pseudomonas* infection and in patients with FEV~1~ \>50% with risk factors ([@b41-copd-2-191]) (Figure [6](#f6-copd-2-191){ref-type="fig"}).

The appropriate use of moxifloxacin in patients with exacerbated chronic bronchial disease and clear criteria of bacterial infection may improve the short- and long-term clinical outcome. Restriction of the use of fluoroquinolones, such as moxifloxacin, in patients with acute bronchitis, suspected viral infections or benign infections that can be successfully treated with older antibiotics will help to preserve the antibacterial activity of the class. The use of the most active fluoroquinolone first ("use the best first") may also contribute to preserve the antibacterial activity of all quinolones and allow its use in patients who really benefit from the better outcome obtained with moxifloxacin. Physicians need to be familiar with criteria for suspecting bacterial infection in exacerbated patients and identify risk factors for relapse in order to indicate the use of moxifloxacin according to local and international guidelines.

![Eradication rates for *H. influenzae* in exacerbations of CB treated with moxifloxacin or macrolides. Derived from [@b53-copd-2-191].](copd-2-191f1){#f1-copd-2-191}

![Results of the meta-analysis of clinical trials with moxifloxacin in exacerbations of CB and COPD. Data obtained from 9 studies including 3,905 patients. Reproduced with permission from [@b42-copd-2-191]. Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis. *Arch Bronconeumol*, 43:22--28. Copyright © 2007 Elsevier.](copd-2-191f2){#f2-copd-2-191}

![The "fall and rise" hypothesis of bacterial exacerbations of COPD.\
**Note:** Some patients with COPD have bacterial colonization of the lower airways. This colonisation is usually due to potentially pathogenic microorganisms (PPMs) in low concentrations (low colony forming units \[CFU\]/mL). Under special circumstances, these PPMs may proliferate and produce increasing inflammatory reaction in the host. When this proliferation exceeds a threshold, symptoms of acute exacerbation may appear. Under antimicrobial therapy, CFU/mL decrease, and when the threshold is crossed, clinical symptoms will disappear. When the intensity and speed of bactericidal activity of the antimicrobial increases (AB2), recovery will be more rapid and time to the next exacerbation will be prolonged. Antimicrobial activity will produce a "fall" in bacterial concentrations, which if not completely eradicated after the pressure of antimicrobial disappears, will "rise" again. Some modifying factors (risk factors, see Table [4](#t4-copd-2-191){ref-type="table"}) may change the threshold of clinical symptoms. Modified from [@b33-copd-2-191].](copd-2-191f3){#f3-copd-2-191}

![Mean cost per patient incurred by treatment failures of exacerbations of CB and COPD in each group. Derived from [@b26-copd-2-191].](copd-2-191f4){#f4-copd-2-191}

![The "virtuous circle" of antibiotic treatment of exacerbations of CB and COPD. Derived from [@b13-copd-2-191].](copd-2-191f5){#f5-copd-2-191}

![Algorithm of antibiotic treatment of ambulatory patients with exacerbations of COPD from the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) and the Spanish Society of Geriatry and Gerontology (SEEG). Derived from [@b41-copd-2-191].\
**Note:** \*Except in patients with risk factors for infection with *P. aeruginosa*, such as impaired lung function, bronchiectasis, and prior use of antibiotics ([@b16-copd-2-191];[@b36-copd-2-191]; [@b50-copd-2-191]).](copd-2-191f6){#f6-copd-2-191}

###### 

Minimum inhibitory concentrations (MIC) of moxifloxacin and other quinolones against common respiratory pathogens

                                                                     **MIC~90~ (mg/L)**                               
  ------------------------------------------------------------------ -------------------- ------------- ------------- ------------
  *S. pneumoniae*                                                                                                     
    penicillin-sensitive[a](#tfn2-copd-2-191){ref-type="table-fn"}   0.06--0.25           1--2          1--2          0.12--0.25
    penicillin-resistant[b](#tfn3-copd-2-191){ref-type="table-fn"}   0.12--0.25           1--2          1--2          0.12--0.25
  *S. aureus*                                                                                                         
    methicillin-sensitive                                            0.12                 0.5--1        0.25          0.06
    methicillin-resistant                                            2                    32--128       16            2
  *M. catarrhalis*                                                                                                    
    beta-lactamase positive                                          0.012--0.06          0.015--0.06   0.06--0.094   0.03
    beta lactamase negative                                          0.012--0.06          0.015--0.06   0.06          0.03
  *H. influenzae*                                                                                                     
    beta-lactamase positive                                          0.03--0.06           0.015--0.03   0.03--0.47    0.015
    beta lactamase negative                                          0.03--0.06           0.015--0.03   0.03--0.32    0.015

Adapted from [@b5-copd-2-191].

^a^penicillin sensitive indicates a penicillin MIC of ≤0.06 μg/mL.

^b^penicillin resistant or non-susceptible indicates an MIC ≥0.1 μg/mL.

###### 

Tissue concentrations by site 10 hours after oral administration of 400 mg of moxifloxacin

  **Site**                  **Tissue concentration**                             **Plasma ratio**
  ------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------
  Plasma                    3.1 mg/L                                             n/a
  Saliva                    3.6 mg/L                                             0.75--1.3
  Blister fluid             1.61 mg/L                                            1.71
  Bronchial mucosa          5.4 mg/kg                                            1.7--2.1
  Alveolar Macrophages      56.7 mg/kg                                           18.6--70.0
  Epithelial lining fluid   20.7 mg/L                                            5--7
  Interstitial fluid        1.0[a](#tfn5-copd-2-191){ref-type="table-fn"} mg/L   0.8--1.4[a](#tfn5-copd-2-191){ref-type="table-fn"}^,^[b](#tfn6-copd-2-191){ref-type="table-fn"}

Data from [@b68-copd-2-191]; [@b69-copd-2-191]; [@b71-copd-2-191].

^a^unbound concentration.

^b^from 3 hours up to 36 hours post dose.

n/a, not applicable.

###### 

Main pharmacokinetic/pharmacodynamic parameters of moxifloxacin after an oral dose of 400 mg

  ----------------------------------------- ---------------------
  Bioavailability                           90%
  C~max~                                    3--4 mg/L
  T~max~                                    1--2 h
  Mean half-life                            13 h
  Binding to plasma proteins                \<40%
  Steady state volume of distribution       2--3 L/kg
  Renal clearance                           24--53 mL/min
  Total body clearance                      179--246 mL/min
  AUC                                       35--45 mg.h L^−1^
  C~max~/MIC~90~ (pneumococcus)             25--35
  AUC~24h~/MIC~90~ or AUIC (pneumococcus)   192--400 mg.h L^−1^
  ----------------------------------------- ---------------------

Data from [@b68-copd-2-191]; [@b69-copd-2-191].

**Abbreviations:** C~max~, maximal or peak plasma concentration; T~max~, time to C~max~;

AUC, area under the curve; AUIC, area under the inhibition curve; MIC, minimum inhibitory concentration.

###### 

Risk factors for relapse after ambulatory treatment of exacerbations of chronic bronchitis and COPD

  ---------------------------------------------------------------------------
  **1. Risk factors for frequent exacerbations (more than two per year)**
    Increasing age
    Severity of FEV~1~ impairment
    Chronic bronchial mucus hypersecretion
    Frequent past exacerbations
    Daily cough and wheeze
    Bronchitic symptoms
  **2. Risk factors for relapse**
    Coexisting cardiopulmonary disease
    Increasing number of previous visits to the GP for respiratory problems
    Increasing number of previous exacerbations
    Increasing baseline dyspnoea
    Severity of FEV~1~ impairment
    Use of home oxygen
  **3. Risk factors for hospital admission**
    Significant comorbidities
    Severity of FEV~1~ impairment
    High admission rates for previous exacerbations
    Three or more admissions previous year
    Underprescription of LTOT
    Lack or reduction in physical activity
  ---------------------------------------------------------------------------

From [@b1-copd-2-191]; [@b15-copd-2-191]; [@b31-copd-2-191]; [@b43-copd-2-191], [@b46-copd-2-191]); [@b57-copd-2-191]; [@b62-copd-2-191].

**Abbreviations:** LTOT, long-term oxygen therapy.

###### 

Clinical success rates with moxifloxacin and comparators in patients belonging to risk groups in clinical trials of exacerbations of chronic bronchitis and COPD

  **Risk factor**                           **Moxifloxacin**   **Comparator/s**                                   **p value**
  ----------------------------------------- ------------------ -------------------------------------------------- -------------------------------------------------
  Age \>60 years                            46/51 (90.1%)      47/52 (90.4%)                                      1.00[a](#tfn14-copd-2-191){ref-type="table-fn"}
  167/184 (90.8%)                           161/181 (89.0%)    0.081[b](#tfn15-copd-2-191){ref-type="table-fn"}   
  145/152 (95.4%)                           122/137 (89.1%)    0.048[c](#tfn16-copd-2-191){ref-type="table-fn"}   
  More than 3 exacerbations previous year   36/42 (85.7%)      30/35 (85.7%)                                      1.00[a](#tfn14-copd-2-191){ref-type="table-fn"}
  138/160 (86.3%)                           136/160 (85.0%)    0.043[b](#tfn15-copd-2-191){ref-type="table-fn"}   
  111/118 (84.1%)                           103/110 (83.6%)    NS[c](#tfn16-copd-2-191){ref-type="table-fn"}      
  Cardiopulmonary comorbidity               22/26 (84.6%)      15/19 (78.9%)                                      0.74[a](#tfn14-copd-2-191){ref-type="table-fn"}
  21/25 (84.0%)                             19/28 (67.9%)      0.010[b](#tfn15-copd-2-191){ref-type="table-fn"}   
  192/202 (95.0%)                           166/185 (89.7%)    0.054[c](#tfn16-copd-2-191){ref-type="table-fn"}   
  Concomitant use of oral corticosteroids   33/38 (86.8%)      28/32 (87.5%)                                      1.00[a](#tfn14-copd-2-191){ref-type="table-fn"}
  140/160 (87.5%)                           105/128 (82%)      0.027[b](#tfn15-copd-2-191){ref-type="table-fn"}   
  48/50 (96%)                               37/44 (84.1%)      NS[c](#tfn16-copd-2-191){ref-type="table-fn"}      
  FEV~1~ (%) \< 50%                         70/119 (58.0%)     69/130 (53.1%)                                     0.36[d](#tfn17-copd-2-191){ref-type="table-fn"}
  66/69 (95.6%)                             67/69 (97.1%)      NS[c](#tfn16-copd-2-191){ref-type="table-fn"}      

Adapted from [@b42-copd-2-191].

^a^[@b67-copd-2-191];

^b^[@b73-copd-2-191];

^c^[@b59-copd-2-191];

^d^[@b74-copd-2-191].

NS = nonsignificant differences; p value not reported in the original publication.

###### 

A summary of clinical trials with moxifloxacin (400 mg once daily) in E-CB and E-COPD

                                                                                                                                        **Outcomes by treatment group**         
  ---------------------------- --------------------------- ------------------------------ --------------------------------------------- --------------------------------- ----- -----
  [@b7-copd-2-191]             Randomized, double-blind    E-CB, N = 926                  0--6 days post-treatment                      5-day MOX (n = 312)               89%   94%
  10-day MOX (n = 302)         91%                         95%                                                                                                                  
  10-day CLR (n = 312)         91%                         91%                                                                                                                  
  [@b73-copd-2-191]            Randomized, double-blind    E-CB Type I/II, N = 649        7 days post-treatment                         5-day MOX (n = 322)               89%   77%
  7-day CLR (n = 327)          88%                         62%                                                                                                                  
  [@b12-copd-2-191]            Randomized, double-blind    E-CB, N = 567                  14--21 days post-treatment                    5-day MOX (n = 283)               88%   95%
  5-day AZM (n = 284)          88%                         94%                                                                                                                  
  [@b74-copd-2-191]            Randomized, double-blind    E-CB Type I, N = 730           7--10 days post-treatment                     5-day MOX (n = 354)               87%   91%
  7-day comparator (n = 376)                                                                                                                                                    
  (AMX, CLR or CFU)            84%                         81%                                                                                                                  
  [@b23-copd-2-191]            Randomized, open-label      E-CB, N = 124                  14--21 days post-treatment                    5-day MOX (n = 62)                85%   n/a
  5-day AZM (n = 62)           88%                         n/a                                                                                                                  
  [@b45-copd-2-191]            Observational, open-label   E-COPD; FEV~1~ \<50% N = 441   30 days post-treatment; relapse-free period   5-day MOX (111 AEs)               66%   n/a
  7-day comparator (503 AEs)   65%                                                                                                                                              
  (AMX, CLR or CFU)                                                                                                                                                             
  [@b18-copd-2-191]            Randomized, open-label      E-CB,Types I and II; N = 423   10 days post-treatment                        5-day MOX                         91%   92%
  7-day CRO                    89%                         91%                                                                                                                  
  [@b59-copd-2-191]            Randomized, open-label      E-CB, N = 512                  14 days post-treatment                        5-day MOX                         96%   88%
  7-day AMX-CLA                92%                         90%                                                                                                                  
  [@b24-copd-2-191]            Observational, open-label   CA-RTIs E-CB; N = 7944         3--10 days post-treatment                     5- to 10-day MOX                  97%   n/a
  [@b29-copd-2-191]            Open-label                  E-CB Type I, N = 328           12 days from treatment onset                  5-day MOX                         91%   n/a
  [@b20-copd-2-191]            Randomized, double-blind    E-CB, N = 461                  7--21 days post-treatment                     5-day MOX                         93%   96%
  7-day LEV                    94%                         96%                                                                                                                  
  [@b48-copd-2-191]            Observational, open-label   E-CB types I and II N = 1456   10 days from treatment onset                  5-day MOX                         97%   n/a
  7-day CLR                    94%                                                                                                                                              
  7-day AMX-CLA                93%                                                                                                                                              
  [@b67-copd-2-191]            Randomized, open-label      E-CB types I and II N = 153    14 days from treatment onset                  5-day MOX                         88%   91%
  7-day AMX-CLA                89%                         70%                                                                                                                  
  [@b72-copd-2-191]            Randomized, double-blind    E-CB; N = 437                  7--14 days post-treatment                     5-day MOX                         91%   93%
  7-day LEV                    94%                         94%                                                                                                                  
  [@b46-copd-2-191]            Observational, open-label   E-CB, N = 5737                 7 days post-treatment                         5- to 10-day MOX                  93%   n/a

Updated from [@b34-copd-2-191].

**Abbreviations:** AMX, amoxicillin; AMX-CLA, amoxicillin-clavulanate; AZM, azithromycin; CA-RTIs, community-acquired respiratory tract infections; CFU, cefuroxime-axetil; E, exacerbation; CLR, clarithromycin; CRO, ceftriaxone; E-CB, exacerbation of chronic bronchitis; E-COPD, exacerbation of chronic obstructive pulmonary disease; LEV, levofloxacin; MOX, moxifloxacin; n/a, not assessed.
